# Why a growth hormone study might also measure cortisol

- Article ID: research-074
- Product: CJC-1295 (No DAC) / GHRP-2 (cjc-1295-ghrp-2-674)
- Canonical page: https://heritagebiolabs.com/research-library/articles/074-why-a-growth-hormone-study-might-also-measure-cortisol
- Product collection: https://heritagebiolabs.com/research-library/products/cjc-1295-no-dac-ghrp-2
- Product page: https://heritagebiolabs.com/product/cjc-1295-ghrp-2-674
- Reading focus: Methods & identity (Reading focus is a navigational tag, not an evidence grade.)
- Source years: 2024, 2026

> Educational article about published research. For research use only; not medical advice. Literature does not establish the identity, purity or activity of a purchased lot, and studies of individual components do not validate a blend.

Peptides are short amino-acid chains linked by peptide bonds, and some help carry signals between endocrine organs. CJC-1295 (No DAC) / GHRP-2 pairs a label commonly used for Mod GRF (1–29), a modified relative of growth hormone–releasing hormone, with GHRP-2, a synthetic six-amino-acid peptide also called pralmorelin. What else might need to be measured when two compounds are grouped under a growth hormone research question? [1, 2]

A September 2026 study reviewed records from 69 people who had undergone tests for possible secondary adrenal insufficiency. In that condition, the adrenal glands produce too little cortisol because the signals from the brain or pituitary gland are inadequate. The researchers compared tests in an effort to distinguish a hypothalamic origin from a pituitary origin. In a subgroup with a normal cortisol response to corticotropin-releasing hormone, the cortisol response to a GHRP-2 challenge showed diagnostic information in that dataset. [1]

The experiment matters to the combination question because GHRP-2 can be studied through an adrenal endpoint as well as through growth hormone. Cortisol and growth hormone come from different organs and represent different responses. The result reflects a retrospective review in a particular patient population, with the diagnostic categories and cutoffs defined in the study. It needs independent validation before the same findings can be expected in another group. [1]

The 2026 work evaluated GHRP-2 as an individual test agent. It did not include the no-DAC peptide or evaluate the named pairing. No recent primary study of the exact pair was identified. The new result gives a concrete reason to keep adrenal measurements separate from the growth hormone endpoint when assessing evidence about either substance. [1, 2]

## Sources

1. Okada N et al. Differentiating hypothalamic from pituitary adrenal insufficiency: underlying causes and diagnostic utility of the corticotropin-releasing hormone and growth hormone-releasing peptide-2 stimulation tests. Endocrine Journal (publication 2026-09-11). <https://pubmed.ncbi.nlm.nih.gov/42732957/>
2. U.S. Food and Drug Administration. December 4, 2024 Pharmacy Compounding Advisory Committee (PCAC) Meeting. FDA briefing document on CJC-1295-related bulk drug substances (publication 2024-12-04). <https://www.fda.gov/media/183819/download>

## Provenance

Article titles, body paragraphs and numbered citations extracted without rewriting from owner-supplied Word volumes. Product mappings use exact catalog labels; reading-focus tags and excerpts are navigational metadata. No independent peer-review or comprehensive source verification is claimed. Source volume: Peptide Research Articles 015 - CJC-1295 With DAC and CJC-1295 (No DAC) GHRP-2.docx; article 74; content SHA-256 90270025db6b4738a00307d219ffe8ed10b9016097998fd847d908eef0b65c56.
